Evidence map›Paper›PMID 26766592›Full record

ArticleCancer cell2016

An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.

A Ari Hakimi, Ed Reznik, Chung-Han Lee, Chad J Creighton, A Rose Brannon, Augustin Luna, B Arman Aksoy, Eric Minwei Liu, Ronglai Shen, William Lee and 9 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05119010 (A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma), which is not on this map. Cited by 510 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
510citing papers in PubMed, 2 pooled it
24.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05119010 naterminatednot on this mapstarted 2023, after this paper: background citation

A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell Carcinoma

TypeinterventionalSponsorGustave Roussy, Cancer Campus, Grand ParisRan2023 to 2024Enrolled3ConditionsMetastatic Renal Cell CarcinomaArmsContinuous ketogenic diet, Discontinuous ketogenic diet, beta-hydroxybutyrate (BHB) supplementation
3 · Its place in the literature

Who cites it

510 citing papers in PubMed, 2 syntheses or guidelines pooled it, 830 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Progress in management of advanced clear-cell renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review

450 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

A Ari Hakimi *
Ed Reznik *
Chung-Han Lee
Chad J Creighton
A Rose Brannon
Augustin Luna
B Arman Aksoy
Eric Minwei Liu
Ronglai Shen
William Lee
Yang Chen
Steve M Stirdivant
Paul Russo
Ying Bei Chen
Satish K Tickoo
Victor E Reuter
Emily H Cheng
Chris Sander
James J Hsieh
Memorial Sloan Kettering Cancer Center · USBaylor College of Medicine · USMetabolon (United States) · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9M
MSKCC Center for Translational Cancer Genomic AnalysisU24CA143840 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LADANYI, MARC, SANDER, CHRIS · 2009 to 2016
$11.5M
The BCM Tumor Genome Characterization CenterU24CA143843 · NCI · BAYLOR COLLEGE OF MEDICINE · PI GIBBS, RICHARD A, WHEELER, DAVID ANDREW · 2009 to 2013
$9.5M
Translational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0M
Molecular Mechanisms of Impaired DAN Damage Response in Leukemia PathogenesisR01CA138505 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HSIEH, JAMES J · 2013 to 2015
$1.0M
NCI NIH HHS 5T32CA160001NCI NIH HHS 5U24CA143843NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA125123NCI NIH HHS P30CA125123NCI NIH HHS R01 CA138505NCI NIH HHS T32 CA160001NCI NIH HHS U24 CA143840
6 · The paper itself

Abstract

Dysregulated metabolism is a hallmark of cancer, manifested through alterations in metabolites. We performed metabolomic profiling on 138 matched clear cell renal cell carcinoma (ccRCC)/normal tissue pairs and found that ccRCC is characterized by broad shifts in central carbon metabolism, one-carbon metabolism, and antioxidant response. Tumor progression and metastasis were associated with metabolite increases in glutathione and cysteine/methionine metabolism pathways. We develop an analytic pipeline and visualization tool (metabolograms) to bridge the gap between TCGA transcriptomic profiling and our metabolomic data, which enables us to assemble an integrated pathway-level metabolic atlas and to demonstrate discordance between transcriptome and metabolome. Lastly, expression profiling was performed on a high-glutathione cluster, which corresponds to a poor-survival subgroup in the ccRCC TCGA cohort.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellGene Expression ProfilingGene Expression Regulation, NeoplasticGenetic Predisposition to DiseaseHumansKidney NeoplasmsMetabolomicsNeoplasm StagingPrognosisBiomarkers, Tumor

Identifiers

PMID26766592
PMCPMC4809063
OpenAlexW2234445408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.